POM stock forecast, quote, news & analysis
Pomdoctor Ltd is an online medical services platform for chronic diseases in China... Show more
Why PomDoctor (POM) Stock Is Up +114% in the Last 30 Days
Key Takeaways
- PomDoctor Limited (POM) shares climbed roughly 114% over the trailing 30-day period, rising from about $0.86 to around $1.84 amid extreme intraday swings.
- The advance was propelled by a dramatic late-October surge—including a single-session spike to $3.01 on unusually heavy volume—rather than a steady fundamental re-rating.
- A 3-for-1 share ratio change took effect on October 21, 2026, following an earlier ADS ratio adjustment, which has reshaped share counts and price comparability.
- Company messaging around an AI-powered chronic disease management strategy has kept the micro-cap name in the trading spotlight.
- The move remains highly speculative: POM is a low-float Chinese ADR that has declined sharply from levels well above $100 over the past year.
- For additional data, explore Price Targets, Earnings, and Forecast pages to review analyst and model-based views on the ticker.
- Discover top-performing automated strategies in the Trending AI Robots section to see how AI-driven trading bots are positioning across the market.
PomDoctor (POM) Company Overview and Market Position
PomDoctor Limited is a China-based online medical services platform that specializes in chronic disease management and pharmaceutical services. The company operates through two primary segments: an internet hospital business that provides online consultations, prescription renewal, and chronic disease management (CDM) services, and a pharmaceutical supply chain business that offers supply chain management and platform operations to other pharmaceutical platforms. Headquartered in Guangzhou, China, the company is listed on the Nasdaq Global Market as an American Depositary Receipt (ADR).
Investors follow POM primarily because of its positioning at the intersection of digital healthcare, pharmaceutical distribution, and artificial intelligence. In recent quarters, the company has emphasized a shift toward AI-driven predictive healthcare, wearable-enabled monitoring, and healthcare data assets. However, as a micro-cap ADR with a limited float and a history of sharp price swings, the stock tends to trade on sentiment, corporate action announcements, and speculative flows as much as on its underlying operating results.
PomDoctor (POM) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, POM advanced roughly 114%, climbing from a closing level near $0.86 in early October to approximately $1.84 in early November. The path was anything but linear. The shares bottomed near $0.43 in mid-October before staging a dramatic surge on October 21, 2026, when the stock closed at $3.01 on volume of roughly 48.8 million shares—a multiple of its typical activity. The price subsequently pulled back and has since stabilized in the $1.10–$2.00 range.
The quarterly trend tells a similar story of recovery off a deeply depressed base. From levels near $0.86 in early August, the stock is up more than 100% over the trailing three months. That advance, however, was preceded by a multi-month decline through September and early October, and the rebound has been driven overwhelmingly by a handful of high-volume sessions rather than by sustained, incremental buying.
What Drove POM Stock Price in the Last 30 Days
The most visible catalyst was the extraordinary volatility surrounding the company's share structure. A 3-for-1 share ratio change took effect on October 21, 2026, following an ADS ratio adjustment that became effective in June. These corporate actions altered the number of shares outstanding and reset the price levels at which the stock trades, contributing to the abrupt repricing and the surge in trading activity observed around late October.
Beyond the structural changes, the move was amplified by a low-float dynamic and speculative retail interest typical of heavily discounted micro-cap ADRs. The company also maintained a steady cadence of public communications around its AI-enabled chronic disease management strategy, including its healthcare data asset strategy and a "healthcare intelligence flywheel" growth narrative. While these announcements carried no new financial guidance, they kept the ticker in front of momentum-focused traders. The stock's sharp decline over the preceding year meant that even a partial recovery translated into a triple-digit percentage gain from a very low base.
What Drove POM Stock Performance Over the Last Quarter
The broader multi-month trend has been shaped by a combination of corporate actions and an ongoing strategic repositioning. In July 2026, the company announced it had regained compliance with the Nasdaq bid price requirement, removing a near-term delisting overhang. That milestone was followed by a series of releases detailing the company's push into AI-powered predictive healthcare, smart wearables, and healthcare data infrastructure, alongside its fiscal 2025 results reported in May.
At the same time, the stock's dramatic fall from its prior-year highs left it trading at a fraction of its former value, creating conditions ripe for outsized percentage swings on any shift in sentiment. The quarter's gains, therefore, reflect a fragile recovery in investor confidence rather than a confirmed turn in fundamentals, and the shares remain subject to unusually wide daily ranges.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots drawn from a broader platform that operates hundreds of automated strategies across thousands of tickers. Only the top-performing and most relevant bots appear in this section, giving traders a focused view of strategies that are currently demonstrating notable results. The bots vary widely in approach, holding timeframe, and performance metrics, ranging from short-term momentum models to longer-horizon technical strategies. For investors seeking a data-driven complement to manual research, browsing this section can offer a useful snapshot of how automated systems are navigating current market conditions.
POM Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, several factors are likely to shape POM's trajectory. First, any update on the company's financial performance—particularly revenue growth in its internet hospital and pharmaceutical supply chain segments—will matter more than the AI narrative alone. Second, the durability of the recent AI-driven healthcare strategy, including whether the company can convert its data and wearable initiatives into measurable revenue, will be closely watched. Third, corporate structure remains a live issue: further ADS ratio or share count adjustments could introduce additional volatility and complicate price comparisons.
Macroeconomic conditions in China, regulatory developments affecting digital health and pharmaceutical e-commerce, and the persistent risk of low-float price swings are also important considerations. Given the stock's history of rapid, sentiment-driven moves, investors should expect continued volatility and should treat percentage gains from a depressed base with caution. This discussion is informational and is not a recommendation to buy or sell any security.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
POM's Stochastic Oscillator is remaining in oversold zone for 3 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on POM as a result. In 18 of 20 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 90%.
POM moved above its 50-day moving average on October 21, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for POM crossed bullishly above the 50-day moving average on October 21, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 2 of 2 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +43.16% 3-day Advance, the price is estimated to grow further. Considering data from situations where POM advanced for three days, in 56 of 63 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
Bearish Trend Analysis
The 10-day RSI Indicator for POM moved out of overbought territory on October 22, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 4 similar instances where the indicator moved out of overbought territory. In 4 of the 4 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for POM turned negative on November 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 6 similar instances when the indicator turned negative. In 5 of the 6 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where POM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
POM broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 28 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: POM's P/B Ratio (0.000) is slightly lower than the industry average of (1.378). P/E Ratio (0.000) is within average values for comparable stocks, (-2.174). POM's Projected Growth (PEG Ratio) (0.000) is very low in comparison to the industry average of (0.947). Dividend Yield (0.000) settles around the average of (0.246) among similar stocks. P/S Ratio (0.043) is also within normal values, averaging (2.504).
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. POM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. POM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 100, placing this stock worse than average.
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry DrugstoreChains